Zobrazeno 1 - 10
of 64
pro vyhledávání: '"JM Ferrari Piquero"'
Publikováno v:
Section 4: Clinical pharmacy services.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::2fd5909e4d2a5fecce9ad11aa9655da1
https://doi.org/10.1136/ejhpharm-2023-eahp.67
https://doi.org/10.1136/ejhpharm-2023-eahp.67
Autor:
JA Hernandez Ramos, S Pablos Bravo, M Rolo, MA Bruni Montero, A Gonzalez Gomez, A Castro Frontiñan, JM Ferrari Piquero
Publikováno v:
Late breaking abstracts.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::73834219f33f765109de4fb16a3e8767
https://doi.org/10.1136/ejhpharm-2023-eahp.369
https://doi.org/10.1136/ejhpharm-2023-eahp.369
Autor:
JA Hernandez Ramos, S Cortijo Cascajares, JM Caro Teller, MA Bruni Montero, S Ortiz Perez, B Sanchez Sanz, A Gonzalez Gomez, JM Ferrari Piquero
Publikováno v:
Section 4: Clinical pharmacy services.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::4c7777fedc453bf66e61a6686767ea54
https://doi.org/10.1136/ejhpharm-2022-eahp.191
https://doi.org/10.1136/ejhpharm-2022-eahp.191
Autor:
B Sanchez, JM Caro Teller, I Gonzalez Barrios, A Hernandez Ramos, Á Gonzalez Gomez, MÁ Bruni Montero, A Castro Frontiñan, JM Ferrari Piquero
Publikováno v:
Section 5: Patient safety and quality assurance.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::c2743951c1fe240cb7878b838d5674c5
https://doi.org/10.1136/ejhpharm-2022-eahp.284
https://doi.org/10.1136/ejhpharm-2022-eahp.284
Autor:
Á González Gómez, JM Caro Teller, O Serrano Garrote, B Sánchez Sanz, JA Hernández Ramos, A Castro Frontiñán, Y Zarcos Moreno, JM Ferrari Piquero
Publikováno v:
Section 2: Selection, procurement and distribution.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::552af34ca3c9d74bf5e83a1fc5de2a95
https://doi.org/10.1136/ejhpharm-2022-eahp.16
https://doi.org/10.1136/ejhpharm-2022-eahp.16
Autor:
C Rosas Espinoza, M Arrieta Loitegui, G. Maestro de la Calle, JM Ferrari Piquero, JM Caro Teller
Publikováno v:
Revista Española de Quimioterapia
RESUMEN Objetivos El incremento de infecciones por bacterias multirresistentes ha obligado a retomar el uso de colistina, antibiótico con nefrotoxicidad conocida. El objetivo del estudio es determinar la incidencia de nefrotoxicidad por colistina en
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c365f92bf7a2afe1584d80fe461c92ac
https://doi.org/10.37201/req/082.2020
https://doi.org/10.37201/req/082.2020
Autor:
O Serrano Garrote, S. Pablos Bravo, JM Ferrari Piquero, A.M. Carro Ruiz, JM Caro Teller, C. Ojeda García, A.M. Guede González
Publikováno v:
Journal of Healthcare Quality Research. 35:364-371
Resumen Objetivo La metodologia Lean Six Sigma (LSS) se basa en la mejora de la productividad y el rendimiento, eliminando los procesos que no aportan valor al cliente y reduciendo la variabilidad. En los ultimos anos se esta incrementando su aplicac
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::6df643be22ad05214c9f4adffcb2bbb1
https://doi.org/10.1016/j.jhqr.2020.04.005
https://doi.org/10.1016/j.jhqr.2020.04.005
Autor:
A Lázaro Cebas, C Rosas Espinoza, S Ortiz Pérez, M Arrieta Loitegui, JM Caro Teller, M. J. Jiménez Cerezo, JM Ferrari Piquero
Publikováno v:
Journal of Healthcare Quality Research. 35:313-318
Resumen Antecedentes y objetivos Los errores de medicacion son el evento adverso mas frecuente de la asistencia sanitaria. La validacion farmaceutica (VF) busca reducirlos. Los objetivos fueron evaluar el impacto de la implementacion de una mejora de
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::0d83a71ca9ebe6507ccf68cd21c05b91
https://doi.org/10.1016/j.jhqr.2020.06.004
https://doi.org/10.1016/j.jhqr.2020.06.004
Autor:
Canales-Siguero, C Rosas-Espinoza, F Martínez De La Torre, S Ortiz-Pérez, JM Ferrari-Piquero, M Arrieta, José Manuel Caro-Teller
Publikováno v:
Section 4: Clinical Pharmacy Services.
Background and importance Dalbavancin is approved for treating complicated skin and soft tissue infections. However, there is growing evidence that other severe gram positive infections could be treated with this antibiotic. Aim and objectives To eva
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::d7931f4488a2701e3bea9ddb0bba6392
https://doi.org/10.1136/ejhpharm-2020-eahpconf.127
https://doi.org/10.1136/ejhpharm-2020-eahpconf.127
Autor:
JM Ferrari Piquero, JM Caro Teller, Cristian R Rosas, M Arrieta Loitegui, S Ortiz Pérez, D Canales, F Martínez De La Torre
Publikováno v:
Section 4: Clinical Pharmacy Services.
Background and importance Ceftaroline is approved for treating complicated skin and skin structure infections (cSSSI), and community acquired pneumonia (CAP). However, there is growing evidence that other severe methicillin resistant staphylococcal i
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::1762c7f0db9a4ddf93b0375ff299c76a
https://doi.org/10.1136/ejhpharm-2020-eahpconf.129
https://doi.org/10.1136/ejhpharm-2020-eahpconf.129